Min Jean Yin

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Targeting the mTOR Pathway in Tumor Malignancy
    Hengmiao Cheng
    Pfizer Worldwide Research and Development, Oncology Research, 10724 Science Center Drive, San Diego, CA 92121, USA
    Curr Cancer Drug Targets 13:267-77. 2013
  2. ncbi The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis
    Min Jean Yin
    SUGEN, Inc, South San Francisco, California 94080 4811, USA
    J Biol Chem 278:52454-60. 2003
  3. ncbi Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model
    Shinji Yamazaki
    Department of Pharmacokinetics, Pfizer Worldwide Research and Development, San Diego, California 92121, USA
    J Pharmacol Exp Ther 338:964-73. 2011
  4. ncbi Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90
    Pramod P Mehta
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California 92121, USA
    Clin Cancer Res 17:5432-42. 2011
  5. ncbi Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells
    Sangita M Baxi
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
    PLoS ONE 7:e48402. 2012
  6. ncbi PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
    Jing Yuan
    Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Mol Cancer Ther 10:2189-99. 2011
  7. ncbi Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target
    Rounak Nassirpour
    Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA
    Mol Cancer Res 8:717-28. 2010
  8. ncbi A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells
    Pramod P Mehta
    Pfizer Worldwide Research and Development, Oncology Research, 10724 Science Center Drive, San Diego, CA 92121, United States
    Cancer Lett 300:30-9. 2011
  9. ncbi Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone
    Pei Pei Kung
    Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA
    J Med Chem 53:499-503. 2010
  10. ncbi Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
    Pei Pei Kung
    Pfizer Global Research and Development, La Jolla Laboratories, 10770, Science Center Dr, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 18:6273-8. 2008

Collaborators

Detail Information

Publications11

  1. ncbi Targeting the mTOR Pathway in Tumor Malignancy
    Hengmiao Cheng
    Pfizer Worldwide Research and Development, Oncology Research, 10724 Science Center Drive, San Diego, CA 92121, USA
    Curr Cancer Drug Targets 13:267-77. 2013
    ..Here we discuss the mechanism of mTOR regulation in tumor malignancy through a variety of signaling pathways and the potential of mTOR inhibitors for the treatment of cancer...
  2. ncbi The serine/threonine kinase Nek6 is required for cell cycle progression through mitosis
    Min Jean Yin
    SUGEN, Inc, South San Francisco, California 94080 4811, USA
    J Biol Chem 278:52454-60. 2003
    ....
  3. ncbi Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model
    Shinji Yamazaki
    Department of Pharmacokinetics, Pfizer Worldwide Research and Development, San Diego, California 92121, USA
    J Pharmacol Exp Ther 338:964-73. 2011
    ..The present results will be helpful in determining the appropriate dosing regimen and guiding dose escalation to achieve efficacious systemic exposure in the clinic...
  4. ncbi Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90
    Pramod P Mehta
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California 92121, USA
    Clin Cancer Res 17:5432-42. 2011
    ..Therefore, an Hsp90 inhibitor may show therapeutic benefit in TNBC by targeting multiple pathways...
  5. ncbi Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells
    Sangita M Baxi
    Oncology Research, Pfizer Worldwide Research and Development, San Diego, California, United States of America
    PLoS ONE 7:e48402. 2012
    ..These results may provide insight into clinical strategies for developing an IGFR-I inhibitor and/or a PDK1 inhibitor in luminal breast cancer patients...
  6. ncbi PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
    Jing Yuan
    Oncology Research Unit, Pfizer Worldwide Research and Development, La Jolla Laboratories, San Diego, CA 92121, USA
    Mol Cancer Ther 10:2189-99. 2011
    ..In summary, PF-04691502 is a potent dual PI3K/mTOR inhibitor with broad antitumor activity. PF-04691502 has entered phase I clinical trials...
  7. ncbi Nek6 mediates human cancer cell transformation and is a potential cancer therapeutic target
    Rounak Nassirpour
    Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, San Diego, CA 92121, USA
    Mol Cancer Res 8:717-28. 2010
    ..Taken together, our data indicate a pivotal role for Nek6 in tumorigenesis and establish Nek6 as a potential target for treatment of a variety of human cancers...
  8. ncbi A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells
    Pramod P Mehta
    Pfizer Worldwide Research and Development, Oncology Research, 10724 Science Center Drive, San Diego, CA 92121, United States
    Cancer Lett 300:30-9. 2011
    ..Our results indicate that Hsp90 inhibitors induce anti-tumor activity in melanoma cells and are likely to show therapeutic benefit in melanoma patients by collaboratively targeting multiple pathways...
  9. ncbi Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (hsp90) molecular chaperone
    Pei Pei Kung
    Pfizer Global Research and Development, La Jolla Laboratories, 10770 Science Center Drive, San Diego, California 92121, USA
    J Med Chem 53:499-503. 2010
    ..This class is exemplified by 14 and 15, which possess improved cell potency and pharmacokinetic profiles compared with the original screening hit...
  10. ncbi Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
    Pei Pei Kung
    Pfizer Global Research and Development, La Jolla Laboratories, 10770, Science Center Dr, San Diego, CA 92121, USA
    Bioorg Med Chem Lett 18:6273-8. 2008
    ..Enantio-pure compounds 31 and 33 were potent in PGA-based competitive binding assay and inhibited proliferation of various human cancer cell lines in vitro, with IC(50) values averaging 20 nM...
  11. ncbi Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difl
    Luke Zehnder
    La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States
    J Med Chem 54:3368-85. 2011
    ..These efforts culminated with the identification of a development candidate (compound 42) which displayed desired PK/PD relationships, significant efficacy in a melanoma A2058 xenograft tumor model, and attractive DMPK profiles...